帕博利珠单抗作为局部晚期或转移性尿路上皮癌二线治疗在瑞典的成本效果
本研究从瑞典医疗保健视角,采用分区生存模型评估帕博利珠单抗对比长春氟宁(基础病例)、紫杉醇或多西他赛单药二线治疗晚期尿路上皮癌的成本效果,时间跨度15年。结果显示帕博利珠单抗较长春氟宁单药平均生存获益1.66年(1.38 QALYs),增量成本€69852,ICER为€50529/QALY;结论认为在€100000/QALY支付意愿阈值下具有成本效果。
要点
- 帕博利珠单抗较长春氟宁单药平均生存获益1.66年(1.38 QALYs),增量成本€69852。
- 帕博利珠单抗对比长春氟宁单药的ICER为€50529/QALY。
- 在€100000/QALY支付意愿阈值下,帕博利珠单抗作为二线治疗具有成本效果。
核心结论
- 结果表明帕博利珠单抗改善生存、增加QALYs,在€100000/QALY支付意愿阈值下作为晚期尿路上皮癌二线治疗具有成本效果。
- 基于试验的成本效果分析提示,在瑞典铂类治疗后晚期尿路上皮癌患者中,帕博利珠单抗相较化疗是具成本效果的选项。
研究设计与样本
- 采用分区生存模型评估帕博利珠单抗对比长春氟宁(基础病例)、紫杉醇或多西他赛单药治疗晚期尿路上皮癌的成本与效果,时间跨度15年。
- 生存终点、不良事件和效用数据来自KEYNOTE-045试验的Kaplan-Meier估计。
- 采用瑞典成本和效用权重估算总成本、质量调整生命年(QALYs)和增量成本效果比(ICERs),并进行确定性和概率敏感性分析。
主要发现
- 基础病例分析中,帕博利珠单抗较长春氟宁单药平均生存获益1.66年(1.38 QALYs),增量成本€69852,ICER为€50529/QALY。
- 帕博利珠单抗对比紫杉醇或多西他赛单药的ICER为€81356/QALY。
- 帕博利珠单抗对比紫杉醇、多西他赛或长春氟宁单药的ICER为€71924/QALY。
关键数值与推荐
- 帕博利珠单抗对比长春氟宁单药的ICER为€50529/QALY。
- 帕博利珠单抗对比紫杉醇或多西他赛单药的ICER为€81356/QALY。
- 帕博利珠单抗对比紫杉醇、多西他赛或长春氟宁单药的ICER为€71924/QALY。
- 支付意愿阈值为€100000/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要KEYNOTE-045的长期随访数据和真实世界数据来验证外推结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urothelial carcinoma (UC) is the most common subtype of bladder cancer. The randomized phase 3 KEYNOTE-045 trial showed that pembrolizumab, used as second-line therapy significantly prolonged overall survival with fewer treatment-related adverse events than chemotherapy for advanced UC. Pembrolizumab has been approved by the European Medicines Agency for the treatment of locally advanced or metastatic UC in adults who have received platinum-containing chemotherapy. Many European countries use cost-effectiveness analysis to inform reimbursement decisions. OBJECTIVE: To assess the cost-effectiveness of pembrolizumab as second-line therapy for the treatment of advanced UC from a Swedish health care perspective. DESIGN, SETTING, AND PARTICIPANTS: We developed a partitioned-survival model to assess the costs and effectiveness of pembrolizumab compared with vinflunine (base case), paclitaxel, or docetaxel monotherapy in patients with advanced UC over a 15-yr time horizon. We obtained Kaplan-Meier estimates for survival endpoints, adverse events, and utility data from KEYNOTE-045. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed parametric extrapolations to estimate overall and progression-free survival beyond the clinical trial period. Swedish costs and utility weights were used to estimate total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We performed deterministic and probabilistic sensitivity analyses to assess the robustness of the model results. RESULTS AND LIMITATIONS: In the base-case analysis, pembrolizumab resulted in a mean survival gain of 1.66 years (1.38 QALYs) at an incremental cost of €69852 and an ICER of €50529/QALY gained versus vinflunine monotherapy. ICERs for other chemotherapies were €81356/QALY for pembrolizumab versus paclitaxel or docetaxel monotherapy, and €71924/QALY for pembrolizumab versus paclitaxel, docetaxel, or vinflunine monotherapy. Long-term follow-up from KEYNOTE-045 and real-world data are needed to validate the extrapolations. CONCLUSIONS: The results indicate that pembrolizumab improves survival, increases QALYs, and is cost-effective as second-line therapy at a willingness-to-pay threshold of €100000/QALY for the treatment of advanced UC. PATIENT SUMMARY: To date, pembrolizumab is the only treatment associated with a significant overall survival benefit compared with chemotherapy in a randomized controlled trial as second-line therapy for advanced urothelial carcinoma. Our trial-based cost-effectiveness analysis suggests that pembrolizumab is a cost-effective option over chemotherapy in patients with advanced urothelial carcinoma after platinum-based therapy in Sweden.
引用
- Srivastava T, Prabhu VS, Li H, et al. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Eur Urol Oncol. 2018. PMID: 31412001. doi:10.1016/j.euo.2018.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。